PolyMedix Inc. Antibiotic Studies Accepted for Presentation at ICAAC

Published: Aug 21, 2012

RADNOR, Pa., Aug. 21, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that six abstracts were accepted for presentation at the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA, September 9-12, 2012. In addition, PolyMedix will participate in an oral symposium. The presentations will be on PolyMedix's defensin-mimetic antimicrobial compounds in development, including results from a Phase 2 clinical study with PolyMedix's lead defensin-mimetic, brilacidin (PMX-30063), in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Staph aureus bacteria and methicillin-resistant Staph aureus (MRSA).

Back to news